HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.

AuthorsC F Spraggs, L R Parham, K Song, L P Briley, T Johnson, M Russo, H Tada, A du Bois, C-F Xu
JournalAnnals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 26 Issue 7 Pg. 1515-7 (Jul 2015) ISSN: 1569-8041 [Electronic] England
PMID25922065 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Apoptosis Regulatory Proteins
  • BCL2L11 protein, human
  • Bcl-2-Like Protein 11
  • Indazoles
  • Indoles
  • Membrane Proteins
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Pyrimidines
  • Pyrroles
  • Quinazolines
  • Sulfonamides
  • Lapatinib
  • pazopanib
  • Sunitinib
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Apoptosis Regulatory Proteins (genetics)
  • Bcl-2-Like Protein 11
  • Gene Deletion
  • Humans
  • Indazoles
  • Indoles (therapeutic use)
  • Lapatinib
  • Membrane Proteins (genetics)
  • Neoplasms (drug therapy, genetics, pathology)
  • Polymorphism, Genetic (genetics)
  • Prognosis
  • Prospective Studies
  • Protein Kinase Inhibitors (therapeutic use)
  • Proto-Oncogene Proteins (genetics)
  • Pyrimidines (therapeutic use)
  • Pyrroles (therapeutic use)
  • Quinazolines (therapeutic use)
  • Signal Transduction (drug effects)
  • Sulfonamides (therapeutic use)
  • Sunitinib

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: